KOSDAQFood & Beverage123840

Nuon

₩1,212▼ 3.35%2026-11-18 close
Market Cap
₩18.9B
Turnover
₩3,314,913
Volume
2.8K
Shares out.
15.6M
PER
—
PBR
0.2×
EPS
-₩2,352
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Nuon: Restructuring Capital and Business Amid Continued Losses

Nuon has shifted its focus toward health functional foods and household goods. It posted an operating profit in Q2 2026 but returned to an operating loss in Q3, so whether the loss structure is resolved remains the key open question.

  1. 1

    Revenue reached KRW 48.2 billion in 2025, the largest year in 2022–2025, and rose for two straight years from 2024.

  2. 2

    Operating losses persisted for four straight years, widening from KRW 7.96 billion in 2022 to KRW 13.4 billion in 2025.

  3. 3

    Operating profit of KRW 182 million in Q2 2026 marked a turn to profit, but Q3 2026 returned to an operating loss of KRW 963 million.

  4. 4

    A rights offering decided in December 2025 and a 10-to-1 reverse stock split approved in March 2026 are reshaping the capital base.

  5. 5

    Net loss attributable to controlling shareholders totaled KRW 36.6 billion over the last four quarters, and operating cash outflow widened to KRW 15.4 billion in 2025.

02

Business structure

Nuon was listed on KOSDAQ in 2010 and operated a vacuum equipment business after a 2013 merger with Hanil Vacuum Machinery. The company was renamed Nuon after an absorption merger completed in 2024, and it halted operations in its vacuum deposition equipment segment in 2025.

Its business now rests on two pillars: a health functional food segment built on individually recognized functional ingredients, and a household goods segment built on the 'Saelim Baekseo' natural organic household and personal care trademark.

Saelim Baekseo was folded in through a small-scale merger, and the company says it plans to diversify into cosmetics, household goods, personal care and pet products. According to Butler's aggregation, the revenue mix in Q2 2026 was 57% household goods and 43% health functional foods.

The Saelim Baekseo brand has drawn over 1.1 million interested customers on Naver's official store, and online growth lifted sales while operating losses continued. The company is also working to add large offline retail chains and overseas sales.

On the health food side, management says product approvals in Taiwan and Vietnam have led to export shipments. The company argues its ingredient portfolio is differentiated, while household goods must compete with established brands in large retail channels. Its largest shareholder holds 90.91%, leaving a small free float.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩16.9B-₩3.8B−22.7%
2025Q4₩8B-₩300M−4.0%
2026Q1₩13.6B-₩2.1B−15.2%
2026Q2₩13.8B₩200M1.3%
2026Q3₩13.7B-₩1B−7.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩6.9B-₩8B-₩59.5B−115.2%−145.0%63.5%
2023₩4.8B-₩10.5B-₩23.2B−217.4%−61.5%76.8%
2024₩16.9B-₩11.7B-₩36.6B−68.9%−37.9%38.3%
2025₩48.2B-₩13.4B-₩38.7B−27.8%−40.0%26.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On a reported annual basis, revenue fell from KRW 6.91 billion in 2022 to KRW 4.82 billion in 2023, a 30.2% decline, then rose to KRW 16.9 billion in 2024 (up 251.5%) and KRW 48.2 billion in 2025 (up 184.2%). Revenue has grown for two straight years since 2024, and 2025 was the largest year in 2022–2025.

Operating losses were KRW 7.96 billion in 2022, KRW 10.5 billion in 2023, KRW 11.7 billion in 2024 and KRW 13.4 billion in 2025, a four-year run of losses with each year's loss larger.

The operating margin improved from -115.2% in 2022 and -217.4% in 2023 to -68.9% in 2024 and -27.8% in 2025, meaning sales growth outpaced the rise in losses, though absolute losses did not shrink.

Net loss attributable to controlling shareholders was KRW 59.5 billion in 2022, KRW 23.2 billion in 2023, KRW 36.6 billion in 2024 and KRW 38.7 billion in 2025. Losses narrowed in 2023 and widened again in 2024 and 2025.

Net loss including non-controlling interests was KRW 38.8 billion in 2025, reported separately from the controlling-shareholder figure. At year-end 2025, total equity was KRW 94.1 billion, of which the controlling shareholders' portion was KRW 96.8 billion, and total liabilities were KRW 24.6 billion.

The debt-to-equity ratio fell from 63.5% in 2022 and 76.8% in 2023 to 38.3% in 2024 and 26.2% in 2025. Operating cash outflow was KRW 7.78 billion in 2022, KRW 7.97 billion in 2023 and KRW 4.97 billion in 2024, then widened to KRW 15.4 billion in 2025.

Quarterly revenue went from KRW 16.9 billion in Q3 2025 to KRW 7.97 billion in Q4 2025, a 52.9% quarter-on-quarter decline, then held at KRW 13.6 billion, KRW 13.8 billion and KRW 13.7 billion across Q1–Q3 2026.

Operating results swung from a KRW 318 million loss in Q4 2025 to a KRW 2.07 billion loss in Q1 2026, a KRW 182 million profit in Q2 2026 and a KRW 963 million loss in Q3 2026.

Net loss attributable to controlling shareholders has been reported for five straight quarters from Q3 2025 to Q3 2026, totaling KRW 36.6 billion over the last four quarters. Q3 2026 revenue fell 18.8% from a year earlier.

05

Industry analysis

In the health functional food market, Nuon's stated differentiator is its individually recognized functional ingredients. Past industry reporting said that these ingredients surpassed red ginseng in market share and production value for the first time since statistics began.

In the same reporting, the company said few domestic players hold ten or more such ingredients. Because this comparison rests on company statements and older industry coverage, it is better read as directional rather than as independent market statistics.

In household goods, online-centered sales make the segment sensitive to retail channel conditions. Management has said the Saelim Baekseo acquisition would help replace home shopping channels and accelerate overseas expansion.

Compared with large food companies such as Orion, CJ Cheiljedang and Nongshim, Nuon's sales scale is small, which may limit its bargaining power with retail partners.

Health functional foods are shaped by regulatory frameworks for ingredient recognition and product approval, so the pace of local approvals and export volumes will condition overseas expansion.

Product approvals and shipments in Taiwan and Vietnam are a starting point, but their share of current revenue is not clearly disclosed in the public filings reviewed. Running two segments with different demand cycles may offer some diversification, but it also means managing two channels and two regulatory regimes.

Within its industry, Nuon sits closer to a small health food company with ingredient differentiation than to the large food groups.

06

Outlook

Management's expansion plans fall into three areas. First, it aims to put Saelim Baekseo products into large offline retail chains to widen a channel that has been mainly online. Second, it intends to grow exports of health food and cosmetics brands that have received approvals in Taiwan and Vietnam.

Third, it plans to broaden its lineup into cosmetics, household goods, personal care and pet products.

On the financing side, a rights offering was announced on December 22, 2025, issuing 12 million common shares at KRW 1,000 per share, with proceeds of KRW 12.0 billion allocated to KRW 8.0 billion of operating funds and KRW 4.0 billion of debt repayment.

Operating funds are set to be used for raw material purchases, with KRW 2.0 billion in 2025 and KRW 6.0 billion in 2026. The debt repayment covers KRW 2.0 billion each of the 14th and 15th convertible bonds.

On the capital side, a 10-to-1 reverse stock split approved on March 13, 2026 was described as aimed at restoring the balance sheet by offsetting accumulated deficits. Whether these steps reduce operating losses should be checked against annual results in the 2026 business report.

With Q3 2026 revenue down 18.8% year on year, the key test is whether offline listings and overseas channels show up as revenue recovery. It also needs to be checked whether the Q2 2026 profit repeats and whether the Q3 loss reflects a temporary cost increase, using future filed figures.

The company has described its direction in terms of expansion. Timing of execution depends on company announcements.

07

Valuation

PER
—
PBR
0.2×
ROE
-44.2%
EPS
-₩2,352
BPS
₩6,081
Dividend per share
₩0

The price-to-book ratio sits below 1x, meaning book equity is larger than market capitalization. Because net losses have continued over the last four quarters, the price-to-earnings ratio cannot be calculated, so earnings-based comparison is not possible at present.

If losses continue, book equity shrinks, so the price relative to net assets should be read alongside the pace of capital erosion.

Total equity of KRW 94.1 billion and total liabilities of KRW 24.6 billion at year-end 2025 show that an asset base remains, but operating cash outflow widened to KRW 15.4 billion in 2025, which suggests capital is being consumed faster. No cash dividend is paid, which limits any dividend-based comparison.

With four years of operating losses, past multiple bands are difficult to apply directly to current results. The rights offering and the reverse split reshaped the capital base, so whether losses shrink after that restructuring is the premise for reading valuation.

Only one quarter, Q2 2026, has been profitable at the operating line, so any recovery in earnings currently rests on a short data series.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Quarterly revenue held near KRW 13 billion

Revenue reached KRW 48.2 billion in 2025, the largest year in 2022–2025. Quarterly revenue of KRW 13.6 billion, KRW 13.8 billion and KRW 13.7 billion in Q1–Q3 2026 has held in the same range for three quarters. Two years of growth since 2024 are being sustained at the quarterly level.

Q3 2026 revenue, however, fell 18.8% from a year earlier, so the quality of the quarterly trend needs continued checking.

Signs of a narrower operating loss

Operating profit of KRW 182 million in Q2 2026 marked a turn to profit. The Q4 2025 operating loss of KRW 318 million was smaller than the KRW 3.84 billion loss in Q3 2025. The operating margin improved from -115.2% in 2022 to -27.8% in 2025. Whether the Q2 2026 profit repeats or was one-off will be visible in upcoming periodic reports.

Ingredient differentiation and a lighter balance sheet

The company says it sells products built on six or more individually recognized ingredients. Product approvals and export shipments in Taiwan and Vietnam give it a concrete starting point overseas. The debt-to-equity ratio fell from 76.8% in 2023 to 26.2% in 2025, which reduces leverage pressure.

09

Bear factors

Prolonged loss structure

Operating losses ran for four straight years, from KRW 7.96 billion in 2022 to KRW 13.4 billion in 2025, while net loss attributable to controlling shareholders went from KRW 59.5 billion to KRW 38.7 billion over the same period. From Q3 2025 to Q3 2026, Q2 2026 is the only quarter with an operating profit. Five straight quarters of controlling-shareholder net losses are the largest bearish factor.

Wider cash outflow and reliance on capital raising

Operating cash outflow widened to KRW 15.4 billion in 2025 from KRW 4.97 billion in 2024. The company approved a rights offering in December 2025 issuing 12 million shares at KRW 1,000, and a 10-to-1 reverse split in 2026 aimed at offsetting accumulated deficits.

Back-to-back capital raising and capital reduction could also be read as a sign that internal cash generation remains limited.

Concentrated ownership and a thin free float

The largest shareholder group holds 90.91% as of July 29, 2026, leaving a low free float. Trading in common shares was suspended from April 13, 2026 until the day before the new shares were listed. A thin float can amplify price volatility, which is a bearish consideration.

10

Risk factors

Financial risk

Operating losses have run for four straight years, and net loss attributable to controlling shareholders totaled KRW 36.6 billion over the last four quarters. Total equity was KRW 94.1 billion at year-end 2025, so continued losses would erode the capital base. Further fundraising could dilute existing shareholders.

Business structure and regulatory risk

Health functional foods are subject to regulatory frameworks covering ingredient recognition and product approvals. Overseas sales depend on building local approvals and export track records. Offline retail listings and overseas expansion for household goods are still plans, so execution is uncertain. With the vacuum equipment business halted, the portfolio now rests on two segments.

Trading and ownership risk

With the largest shareholder group holding 90.91%, the free float is small. Trading was suspended in April 2026 due to a capital reduction. Thin trading volume can increase price swings and make order execution harder.

11

What to watch next

  1. End of December 2026

    Check how the KRW 6.0 billion of 2026 operating funds for raw material purchases appears in the cash flow statement. Whether operating cash outflow narrows is the benchmark for reliance on capital raising.

  2. End of March 2027

    Deadline for the 2026 business report. Compare full-year 2026 revenue, operating loss and controlling-shareholder net loss with 2025, and check whether the Q2 2026 profit carried into the annual result.

  3. May 15, 2027

    Deadline for the Q1 2027 quarterly report. It is the first quarter in which to see whether the Q3 2026 loss was temporary and whether offline listings and overseas channels lift revenue.

  4. Timing not yet set (on company announcement)

    Watch for disclosures or IR updates on offline retail listings for Saelim Baekseo products and export volumes to Taiwan and Vietnam. Timing and scale must be confirmed before shifts in the revenue mix can be assessed.

12

Overall view

Nuon posted the largest revenue of its 2022–2025 period in 2025, at KRW 48.2 billion, but recorded operating losses of KRW 13.4 billion and a controlling-shareholder net loss of KRW 38.7 billion, extending its losses for four straight years.

Quarterly revenue held in the KRW 13 billion range through 2026, and Q2 2026 turned to an operating profit of KRW 182 million, but Q3 2026 returned to an operating loss of KRW 963 million.

The KRW 36.6 billion controlling-shareholder net loss over the last four quarters and the KRW 15.4 billion operating cash outflow in 2025 show that the loss structure has not yet been resolved.

The debt-to-equity ratio fell from 63.5% in 2022 to 26.2% in 2025, and the capital base was reshaped through a rights offering and a reverse split. Bullish factors are the sustained revenue scale, a recent profitable quarter, and individually recognized ingredients with overseas approvals.

Bearish factors are continued losses, a wider cash outflow, and a high largest-shareholder stake with a low free float. The next checkpoints are the annual operating loss in the 2026 business report and the direction of operating profit in Q1 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. butler.works
  2. comp.wisereport.co.kr
  3. m.news.nate.com
  4. edaily.co.kr
  5. digitaltoday.co.kr
  6. news.nate.com
  7. pharm.edaily.co.kr
  8. news.nate.com
  9. judal.co.kr
  10. judal.co.kr
  11. judal.co.kr
  12. cdn.neowiz.com
  13. judal.co.kr
  14. judal.co.kr
  15. datatooza.com
  16. job-post.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis